$5.3m · Pre-Seed · Healthtech · Helsinki, Finland
Switchpoint Bio, a Finnish-US biotech developing blood-based epigenomics tools for drug development, has raised $5.3m in Pre-Seed funding. Treehouse Delmar Investments provided $5m; the company did not name the source of the remaining capital. The funding will support clinical and industry validation, larger clinical and biobank datasets, continued epigenomics and AI development, and hiring in Helsinki and Cambridge, Massachusetts.
Blood samples could shorten feedback in drug trials
Switchpoint is building a measurement platform for pharmaceutical and biotechnology teams that want to see how disease and treatment change patients' biology over time. It combines targeted DNA-methylation profiling from blood, reference data from single-cell studies and AI to identify cell states linked to disease, treatment response and resistance.
The practical advantage is repeatability. Tissue biopsies can be invasive and difficult to collect throughout a trial, while single-cell methods often require fresh samples, specialist laboratories and expensive processing. Switchpoint aims to turn an ordinary blood sample into a more scalable view of the cellular mechanisms behind a drug's effect.
If validated, the platform could become a measurement layer within clinical studies rather than a one-off diagnostic test. Earlier evidence about mechanism and patient response could help drug developers decide which programmes, biomarkers and patient groups deserve more investment. The commercial opportunity therefore depends on fitting the assay and analysis into study protocols and showing that the biological signals are reliable across sites, populations and repeated samples.
Validation is the next commercial test
The company says its first studies focus on autoimmune diseases including systemic lupus erythematosus, and it is discussing initial validation projects with pharmaceutical and biotech companies. Those collaborations matter because scientific resolution alone is not enough: Switchpoint must show that its measurements track meaningful changes in treatment and can be produced consistently at the scale and cost required for clinical research.
Sources checked:
Switchpoint Bio company announcement via STT Info · Tech.eu Funding Explorer
